lower costs directly related to the method (€1,371.16), however associated hospitalisation costs were higher due to longer hospitalisation (5 days versus 4 days).

**Conclusion** Even though CRB is an effective method to induce labour at a lower cost than Propess in our pilot test, a longer hospitalisation length was observed with this device. Further studies are needed to evaluate the efficacy, safety and all direct costs involved in these techniques and also considering other available methods.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

None.

No conflict of interest.

---

**2SPD-020** **EXPIRED MEDICINES AND MEDICAL DEVICES, AN ACROBATIC MANAGEMENT**

S Cayeux*, A Durand, M Moreau, C Vanyghem, M Belhout. CHU Amiens Picardie, Pharmacy, Amiens, France

10.1136/ehjpharm-2019-eahpconf.60

**Background** The supply of health products is a major activity for hospital pharmacists. Its complexity is based on the need to hold sufficient stock at a reasonable cost while avoiding over-stocking of products and therefore money. In our institution, various systems were established to prevent expired medicines such as automated drugs distribution systems with distribution according to the best before date or the first-in first-out principle managed by a warehouse management system. Nevertheless, some drugs and medical devices expire each month.

**Purpose** The aim of this work has been to identify the factors responsible for the lapse in order to optimize inventory management.

**Material and methods** From May 2016 to July 2018, we had identified the products (name, quantity, price) removed from the stock due to lapsing in our hospital pharmacy. For each of them, we had researched the reason for expiration, and we have proposed a solution to optimize stock management.

**Results** Three-hundred and thirty products have been thrown away, which have represented €1 70 149 (€1 44 761 excluding refunds by suppliers). The causes encountered have been: no regular consumption (90 products; 8% of expenses); termination of use (79; 31%); products returned from services (39; 2%); emergency drugs such as antidotes (39; 27%); inadequate management of stocks (36; 8%); and other causes (47; 24%).

The two main corrective actions have been procurement inactivation (30% of cases) and decrease in security threshold (28%).

For 28% of the products, particularly pharmaceutical preparations and emergency drugs, ordering recommendations have been maintained.

**Conclusion** The cessation of needs represents the main item of expenditure, but one product is responsible for half of this cost (24 units at €1,100 each). The amount of expenditure is probably underestimated because the price of pharmaceutical preparations (28 cases) was not charged. Having optimised the settings seems to be efficient because there is no lapse redundancy except for the little-used products for which a minimal stock must be maintained. Optimising the stock is a long term-job which requires the contribution of several stakeholders such as buyer pharmacists, supply and logistic responsible and consumers.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

None.

No conflict of interest.

---

**2SPD-021** **NONCOMPLIANCE OF DATAMATRIX CODES, AN OBSTACLE TO IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE**

S Cayeux*, A Durand, JF Boutigny, C Vanyghem, M Belhout. CHU Amiens Picardie, Pharmacy, Amiens, France

10.1136/ehjpharm-2019-eahpconf.61

**Background** To reduce counterfeit drugs, the serialisation will become mandatory on 9 February 2019. A DataMatrix code will be used to encode each secondary packaging.

This 2D barcode makes it possible to indicate an important number of traceability data in a small area. The technical characteristics of DataMatrix codes were defined in standard ISO/CEI 16022:2006.

Our university hospital is equipped with an automated storage and dispensing system of drugs. Unfortunately, this automat is not able to read the totality of DataMatrix codes. This obliges us to store manually in the automat the products concerned, which increases the duration of reception and the labour cost.

**Purpose** The purpose of this work is to identify the medicines for which the datamatrix code cannot be read by the automat and the causes of this problem.

**Material and methods** In our hospital, a total of 2107 references need to be serialised, including 1252 references stored in our automat.

From June 2018 to September 2018, the products concerned by the impossibility of reading the codes, the laboratories involved and the causes of illegibility were compiled.

**Results** During the period of collection, 107 products from 23 providers have presented a problem of legibility.

This represented 8.5% of products stored in the automat.

The problem has always been the black colour of the background.

**Conclusion** Only one cause of noncompliance was identified, but we should note that our enquiry is not a comprehensive collection of data because we did not receive all the medicines referenced during the mentioned period.

We imagine that other problems could be encountered such as too small Datamatrix codes or shiny backgrounds.

A solution could be the change of reader heads of our automat but this represents an important investment.

The second part of this work will consist in collaboration between pharmacist buyers, pharmaceutical laboratories and equipment manufacturers to encourage the standardisation of the datamatrix codes in order to facilitate compliance with the Falsified Medicines Directive.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Thank you to storekeepers.

No conflict of interest.

---

**2SPD-022** **ON THE ROAD TO SERIALISATION: A PRATICAL APPLICATION**

E Ducet*, E Schwartz, F Plassart, JM Descoutures, JL Pons. Victor Dupouy Hospital, Pharmacy, Argenteuil, France

10.1136/ehjpharm-2019-eahpconf.62

**Background** The Falsified Medicines Directive (FMD) and the Delegated Regulation (DR) 2016/161 will require, from 9 February 2019, hospital pharmacies to check the authenticity of each medicinal product they receive. Our hospital participates in this new process through our automat but this represents an important investment.

The purpose of this work is to identify the medicines and medical devices that need to be serialised, including 1252 references stored in our automat.

From June 2018 to September 2018, the products concerned by the impossibility of reading the codes, the laboratories involved and the causes of illegibility were compiled.

Results During the period of collection, 107 products from 23 providers have presented a problem of legibility.

This represented 8.5% of products stored in the automat.

The problem has always been the black colour of the background.

**Conclusion** Only one cause of noncompliance was identified, but we should note that our enquiry is not a comprehensive collection of data because we did not receive all the medicines referenced during the mentioned period.

We imagine that other problems could be encountered such as too small Datamatrix codes or shiny backgrounds.

A solution could be the change of reader heads of our automat but this represents an important investment.

The second part of this work will consist in collaboration between pharmacist buyers, pharmaceutical laboratories and equipment manufacturers to encourage the standardisation of the datamatrix codes in order to facilitate compliance with the Falsified Medicines Directive.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

Thank you to storekeepers.

No conflict of interest.